FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103608903> ?p ?o ?g. }

• W2103608903 abstract "You have accessJournal of UrologyGeneral & Epidemiological Trends & Socioeconomics: Quality of Life1 Apr 2015MP27-20 IMPACT ON HEALTH RELATED QUALITY OF LIFE FOLLOWING TREATMENT OF UROLOGIC CANCERS: RESULTS OF A PROSPECTIVE STUDY John Oliver DeLancey, Gregory Auffenberg, David Victorson, and Shilajit Kundu John Oliver DeLanceyJohn Oliver DeLancey More articles by this author , Gregory AuffenbergGregory Auffenberg More articles by this author , David VictorsonDavid Victorson More articles by this author , and Shilajit KunduShilajit Kundu More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1182AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Diagnosis with, and treatment for, urologic cancer (kidney, bladder, prostate) can bring a number of stressors that affect patients' quality of life. In order to better understand the trajectory of treatment burden and health related quality of life after treatment, we sought to prospectively evaluate patient-reported quality of life outcomes prior to and following treatment for urologic cancer. METHODS Patients newly diagnosed with kidney, bladder or prostate cancer at our institution were enrolled in an internet-based data collection platform (PROMIS: Patient-Reported Outcomes Measurement Information System) which used validated questionnaires to serially assess quality of life measures related to sexual, urinary and bowel, and emotional outcomes. These questionnaires included the International Index of Erectile Function (IIEF), Cancer Promis supplement (CAPS), and Surgical Outcomes Measurement System (SOMS). Analysis of variance (ANOVA) was used to test for differences in these self-reported measures at enrollment (pre-treatment) and 1, 3, 6 and 12 months following treatment. A total of 105, 32, and 54 patients diagnosed with prostate, bladder and kidney cancer were enrolled in our study and 63, 16, and 30 patients completed each of the follow-up surveys, respectively. RESULTS Differences in mean values for self-reported outcomes are presented in Table 1. Patients treated for prostate cancer had significantly decreased sexual related QOL after treatment. Erectile function and sexual satisfaction were relatively preserved in patients diagnosed with bladder and kidney cancer. All groups reported significant improvement in anxiety following treatment. Depression, pain and sleep were also significantly improved in patients diagnosed with kidney cancer following treatment. Despite decreased sexual function in prostate cancer patients, there was no significant change in satisfaction with results of the treatment in any of the disease states. CONCLUSIONS The impact of treatment of urologic cancers carries significant stressors to quality of life for patients. However, with shared decision making between patients and physicians and management of expectations, patients were satisfied with the results of their treatment. Differences in mean values of quality of life outcomes following treatment for urologic cancer CAPS sexual satisfaction SOMS anxiety SOMS sleep SOMS depression SOMS pain Time Estimate p-value Estimate p-value Estimate p-value Estimate p-value Estimate p-value Prostate 1 mo -7.75 <0.01 -1.68 <0.01 0.51 0.14 -0.61 0.16 0.43 0.32 3 mo -7.00 <0.01 -2.19 <0.01 0.30 0.35 -0.50 0.26 -0.03 0.94 6 mo -8.16 <0.01 -2.56 <0.01 0.12 0.75 -0.58 0.17 0.08 0.87 12 mo -7.04 <0.01 -1.65 <0.01 0.31 0.41 -0.01 0.98 0.40 0.32 Bladder 1 mo -5.61 0.01 -1.49 0.08 1.21 0.06 0.03 0.97 2.20 0.01 3 mo -2.00 0.27 -2.75 <0.01 0.22 0.70 -0.90 0.27 1.17 0.15 6 mo 0.11 0.96 -2.72 <0.01 -0.01 0.99 -0.23 0.77 1.99 0.03 12 mo 0.09 0.96 -3.98 <0.01 0.39 0.59 -1.68 0.08 1.27 0.11 Kidney 1 mo -1.58 0.29 -2.40 <0.01 -0.54 0.27 -1.20 0.05 0.62 0.30 3 mo 0.55 0.67 -3.27 <0.01 -1.33 <0.01 -1.74 <0.01 -1.44 0.02 6 mo 1.24 0.38 -3.82 <0.01 -1.73 <0.01 -1.82 <0.01 -1.62 0.02 12 mo 0.54 0.72 -3.43 <0.01 -2.10 <0.01 -1.79 0.01 -0.91 0.12 Estimates compared to baseline questionnaire values © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e310-e311 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.Metrics Author Information John Oliver DeLancey More articles by this author Gregory Auffenberg More articles by this author David Victorson More articles by this author Shilajit Kundu More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2103608903 created "2016-06-24" @default.
• W2103608903 creator A5052853942 @default.
• W2103608903 creator A5061216686 @default.
• W2103608903 creator A5083112775 @default.
• W2103608903 creator A5086075771 @default.
• W2103608903 date "2015-04-01" @default.
• W2103608903 modified "2023-10-03" @default.
• W2103608903 title "MP27-20 IMPACT ON HEALTH RELATED QUALITY OF LIFE FOLLOWING TREATMENT OF UROLOGIC CANCERS: RESULTS OF A PROSPECTIVE STUDY" @default.
• W2103608903 doi "https://doi.org/10.1016/j.juro.2015.02.1182" @default.
• W2103608903 hasPublicationYear "2015" @default.
• W2103608903 type Work @default.
• W2103608903 sameAs 2103608903 @default.
• W2103608903 citedByCount "0" @default.
• W2103608903 crossrefType "journal-article" @default.
• W2103608903 hasAuthorship W2103608903A5052853942 @default.
• W2103608903 hasAuthorship W2103608903A5061216686 @default.
• W2103608903 hasAuthorship W2103608903A5083112775 @default.
• W2103608903 hasAuthorship W2103608903A5086075771 @default.
• W2103608903 hasConcept C107130276 @default.
• W2103608903 hasConcept C121608353 @default.
• W2103608903 hasConcept C126322002 @default.
• W2103608903 hasConcept C159110408 @default.
• W2103608903 hasConcept C188816634 @default.
• W2103608903 hasConcept C2775871022 @default.
• W2103608903 hasConcept C2779951463 @default.
• W2103608903 hasConcept C2780192828 @default.
• W2103608903 hasConcept C29456083 @default.
• W2103608903 hasConcept C71924100 @default.
• W2103608903 hasConcept C74909509 @default.
• W2103608903 hasConceptScore W2103608903C107130276 @default.
• W2103608903 hasConceptScore W2103608903C121608353 @default.
• W2103608903 hasConceptScore W2103608903C126322002 @default.
• W2103608903 hasConceptScore W2103608903C159110408 @default.
• W2103608903 hasConceptScore W2103608903C188816634 @default.
• W2103608903 hasConceptScore W2103608903C2775871022 @default.
• W2103608903 hasConceptScore W2103608903C2779951463 @default.
• W2103608903 hasConceptScore W2103608903C2780192828 @default.
• W2103608903 hasConceptScore W2103608903C29456083 @default.
• W2103608903 hasConceptScore W2103608903C71924100 @default.
• W2103608903 hasConceptScore W2103608903C74909509 @default.
• W2103608903 hasIssue "4S" @default.
• W2103608903 hasLocation W21036089031 @default.
• W2103608903 hasOpenAccess W2103608903 @default.
• W2103608903 hasPrimaryLocation W21036089031 @default.
• W2103608903 hasRelatedWork W1984684443 @default.
• W2103608903 hasRelatedWork W1990447329 @default.
• W2103608903 hasRelatedWork W2057698464 @default.
• W2103608903 hasRelatedWork W2076536345 @default.
• W2103608903 hasRelatedWork W2153880801 @default.
• W2103608903 hasRelatedWork W2295722933 @default.
• W2103608903 hasRelatedWork W2531350361 @default.
• W2103608903 hasRelatedWork W2962601203 @default.
• W2103608903 hasRelatedWork W2971350735 @default.
• W2103608903 hasRelatedWork W2791475756 @default.
• W2103608903 hasVolume "193" @default.
• W2103608903 isParatext "false" @default.
• W2103608903 isRetracted "false" @default.
• W2103608903 magId "2103608903" @default.
• W2103608903 workType "article" @default.